Short answer
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K current report with the SEC on March 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Reg FD disclosure filed March 2, 2026, signed by CEO Adam S. Grossman.
ADMA BIOLOGICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure filed March 2, 2026, signed by CEO Adam S. Grossman
- No substantive operational or financial data disclosed in the filing text itself: material content likely contained in referenced exhibit
Item 8.01 · Other Events
- $125M ASR with JPMorgan, funded via existing $225M revolving credit facility: part of $500M total buyback program announced May 2025
- Initial delivery ~6.4M shares (~80% of expected total) on/around March 3, 2026 at reference price of $15.57/share
- Final share count based on VWAP over ~5-month term, less agreed discount: company could receive more shares or owe cash/shares at settlement
- ASR signals management confidence in stock value; debt-funded buyback adds leverage risk if business performance softens
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADMA BIOLOGICS, INC. 8-K filings
Get the next ADMA 8-K as it lands
Follow ADMA for push alerts, or ask the research agent what this filing means.